Studies have shown that PUMA expression could potentiate cisplatin sensitivities in some NSCLC cell lines [31], we thus examined whether EZH2 knockdown-caused PUMA induction could also enhance the efficacy of cisplatin in NSCLC cell lines tested. Here, EZH2 is linked to non-small cell lung carcinoma.